Drugs / TRV250
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04201080 | Nov 2019 → Feb 2020 | migraine without aura | Trevena Inc. | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2019-12-12 | Trevena Inc. | Results Trevena Presents Phase 1 Data on TRV250 for Acute Migraine at American College of Neuropsychopharmacology 2019 Annual Meeting trevena.com ↗
TRV250 was well-tolerated up to 30 mg, with a PK profile appropriate for an acute migraine therapy. |
| 2018-06-28 | Trevena Inc. | Results Trevena announces successful completion of Phase 1 study of TRV250 for acute migraine trevena.com ↗
Data from this healthy volunteer study showed safety, tolerability, and pharmacokinetics supporting the advancement of TRV250 to Phase 2 proof of concept evaluation in patients. |
| 2017-11-07 | Trevena Inc. | Results Trevena Reports Third Quarter 2017 Financial Results and Announces New Positive Clinical Trial Data trevena.com ↗
Positive interim Phase 1 data for TRV250 bode well for future clinical development of this exciting potential migraine therapy. |
| 2015-05-14 | Trevena Inc. | Results Trevena Announces Presentation of Preclinical Data for Delta Receptor Compound TRV250 at International Headache Congress trevena.com ↗ |
All press releases naming this drug 5 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRV250 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04201080 ↗ |
| Route | Subcutaneous | “The investigational product (TRV250) will be administered by subcutaneous injection” NCT04201080 ↗ |